A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis- Associated Acute Kidney Inju

Grants and Contracts Details

StatusActive
Effective start/end date4/2/211/25/23

Funding

  • AM Pharma BV: $79,319.00